Delving into the Latest Updates on Epicyte Pharmaceutical, Inc. with Synapse

概览

关联

1

项与 Epicyte Pharmaceutical, Inc. 相关的药物

HX-8

靶点

HSV antigen

作用机制

HSV antigen抑制剂

在研机构-

原研机构

Epicyte Pharmaceutical, Inc.

在研适应症-

非在研适应症

单纯疱疹

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

100 项与 Epicyte Pharmaceutical, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Epicyte Pharmaceutical, Inc. 相关的专利（医药）

登录后查看更多信息

5

项与 Epicyte Pharmaceutical, Inc. 相关的文献（医药）

2003-01-01·Plant Biotechnology 2002 and Beyond

Antibodies from Plants: Breaking the Barriers to Antibody Production

作者: Neil M. Cowen ; Mich B. Hein

Green plants were an important historical source of medicines, and a primary source of humans’ first biopharmaceuticals. Because plants are the most efficient producers of protein on the planet, they are now being tapped as a production source for the fastest growing class of new pharmaceuticals: therapeutic and prophylactic proteins. The list of potential protein-based pharmaceuticals includes structural proteins from viral and bacterial pathogens, human antibodies and other immunoglobulins, defensins, enzymes and unique synthetic or chimeric proteins. Because plants are eucaryotes with a well developed endomembrane system, they have proved particularly efficient in producing complex and multimeric proteins. For complex proteins like immunoglobulins, green plants provide breakthroughs in economics, scale of production and the scope of molecules that can be efficiently manufactured. Producing antibodies in large quantities using professional agronomic corps could dramatically increase the use of antibody therapeutics and facilitate new uses for these medicines. While significant improvements are on the horizon, the basic technology for generating transgenic plants that produce a variety of functional antibodies is now well developed. The current challenge is to integrate this robust technology into the existing regulatory framework for developing safe and effective pharmaceuticals. We are witnessing the evolution of crop stewardship, manufacturing and processing technologies that protect health and safety of the public while delivering cost-effective treatments and preventives for human disease.

2002-11-01·Biotechnology and Genetic Engineering Reviews3区 · 工程技术

Preventing Sexual Transmission of HSV and HIV: the Challenge for Active and Passive Immunization of Mucosal Surfaces

3区 · 工程技术

Review

作者: Whaley, Kevin J. ; Zeitlin, Larry ; Palmer, Carrie

A review discusses active and passive immunization with glycoproteins of herpes simplex virus and envelope proteins of HIV.

2002-04-01·Herpes : the journal of the IHMF

Microbicides for preventing transmission of genital herpes.

Review

作者: Zeitlin, Larry ; Whaley, Kevin J

Available technologies for preventing sexual transmission of genital herpes infection are limited. This article focuses on the ongoing development of a new technology, topical microbicides, for preventing sexually transmitted infection. Recent data evaluating detergent-based spermicides as potential microbicides are reviewed. The first generation of broad-spectrum, non-detergent microbicides that are currently in clinical development, including the sulphated polymer-based inhibitors and acid buffers, are discussed. Finally, the potential of monoclonal antibodies as an example of a specific microbicide in late pre-clinical development is considered.

100 项与 Epicyte Pharmaceutical, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Epicyte Pharmaceutical, Inc. 相关的转化医学

登录后查看更多信息